Comparison of efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients of Type 2 diabetes mellitus
Journal Title: National Journal of Physiology, Pharmacy and Pharmacology - Year 2018, Vol 8, Issue 4
Abstract
Background: Diabetes mellitus is a heterogeneous chronic metabolic disorder principally characterized by persistent hyperglycemia resulting from defects in insulin action and/or insulin secretion. In course of time, prolonged hyperglycemia and associated metabolic aberrations result in tissue toxicity manifested as accelerated atherosclerosis, renoretinal microangiopathy, and neuropathy leading to a variety of vascular, neurological, and focal complications. Aim and Objective: The aim of this study is to evaluate the efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients with Type 2 diabetes mellitus. Materials and Methods: This is a longitudinal interventional study. A total of 60 patients were enrolled in the study. Those patients who were already on metformin 500 mg bid with poor glycemic control were included in the study. These 60 patients were divided into two groups each consisting of 30 patients. Group A patients received glimepiride 1 mg bid and metformin 500 mg bid. Group B patients received vildagliptin 50 mg bid and metformin 500 mg bid. The total period of the study was 3 months. Results: After 3 months of treatment, both the groups caused a significant decline in blood glucose levels both fasting blood sugar (FBS) as well as postprandial blood sugar (PPBS) levels. There was a significant difference between the two groups in reducing the FBS levels and PPBS. Hemoglobin A1c (HbA1c) was also reduced significantly in both groups at 12 weeks. After 3 months of therapy, there was a reduction in HbA1C in B group. The reduction of HbA1C was not statistically significant between the two groups. Adverse effects were more with metformin and glimepiride group at the end of 3 months therapy. There was a significant difference in the incidence of adverse effects between both the groups. Conclusions: Vildagliptin and metformin combination provided better efficacy comparable to that of glimepiride and metformin combination and resulted in better adverse effect profile with lower risks of hypoglycemia and weight gain.
Authors and Affiliations
Harinika Gullapalli, Savithri Desai
Keywords
Related Articles
- EP ID EP487759
- DOI 10.5455/njppp.2018.8.1143618112017
- Views 47
- Downloads 0
A pilot study to evaluate the effect of HAART on gonadal dysfunction in male HIV patients
Background: Derangement of gonadal functions has been reported in association with HIV infection, but data from Indian population are not sufficient. Aims & Objective: To evaluate the effect of highly...
Effectiveness of mind maps as a self-learning tool in 1st year MBBS students of an Indian medical college
Background: The mind map (MM) is a powerful graphic technique that can be applied to improve learning and clearer thinking. MMs can be used as self-learning methods that facilitate understanding of difficult concepts. A...
Effect of coenzyme Q10 on depression paradigms in male Wistar rats and Swiss albino mice
Background: Depression is a major public health concern. Inflammation and oxidative stress have emerged as major contributors to the neuroprogression of depression. There is evidence that there are reduced antioxidant (A...
Association of ABO blood group with different constitutional types
Background: Tridosha and Prakriti are the fundamental principles of Ayurveda which forms the basis of individualized approach of Ayurveda for health and diseases. All individuals have the same blood group system, but dif...
Study of QT interval in pediatric age group
Background: Changes in QT interval is one of the important electrocardiographic parameters which are reported in many clinical conditions not only in adults but also among the pediatric age group. Diseases with a high ri...